Blueprint Medicines(BPMC)在盘中出现大幅下挫,最新报价96.93美元/股,较前一交易日下跌8.27%。
公司前不久公布的2024年第四季度财报显示,第四季度每股亏损0.79美元,超出了分析师此前预计的0.70美元亏损。尽管公司当季销售额1.4637亿美元较去年同期翻番,但净亏损仍在扩大。
业绩表现令投资者失望,加之公司定位于肿瘤及罕见病药物研发,现金流情况短期内难以改观,或是导致股价承压的主因。由于研发周期长、风险高,Blueprint Medicines未来的长期发展仍存在很大不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.